Effect of finerenone combined with telmisartan in the treatment of diabetic nephropathy
胡漪玲 1胡晓鹏 2胡锦晨3
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 漯河市第二人民医院消化肾病科，漯河 462000
2. 周口市中心医院康复科，周口 466000
3. 周口市中心医院 消化内科，周口 466000
折叠
摘要
目的 探讨非奈利酮联合替米沙坦治疗糖尿病肾病(DN)的临床效果。 方法 回顾性抽取2021年5月至2023年4月漯河市第二人民医院收治的DN患者53例，按照治疗方法分为单一组(26例，采用替米沙坦治疗)和联合组(27例，采用非奈利酮联合替米沙坦治疗)。比较两组血糖指标[空腹血糖(FPG)、餐后2 h血糖(2hBG)、糖化血红蛋白(HbA1C)]水平、肾功能指标[血肌酐(Scr)、血尿素氮(BUN)、肾小球滤过率(GFR)]、炎症指标[肿瘤坏死因子－α(TNF－α)、白细胞介素－6(IL－6)]及不良反应发生情况。 结果 治疗后，联合组FPG、2hBG、HbA1C、Scr、BUN、TNF－α、IL－6水平低于单一组(P<0.05)，GFR高于单一组(P<0.05)。联合组不良反应发生率(11.11%，3/27)与单一组(3.85%，1/26)比较，差异未见统计学意义(P>0.05)。 结论 非奈利酮联合替米沙坦治疗DN效果显著，能减轻肾脏炎症，改善胰岛素抵抗，降低血糖水平，改善患者肾功能，且联合用药的不良反应较少。 Objective To investigate the clinical effect of finerenone combined with telmisartan in the treatment of diabetic nephropathy (DN). Methods Fifty-three patients with DN admitted to Luohe Second People’s Hospital from May 2021 to April 2023 were retrospectively selected. And they were divided into a single group (26 cases, treated with telmisartan) and a combination group (27 cases, treated with finerenone combined with telmisartan) according to the treatment method. The levels of blood glucose indexes including fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hBG) and glycosylated hemoglobin (HbA1C), renal function assessed by serum creatinine (Scr), blood urea nitrogen (BUN) and glomerular filtration rate (GFR), inflammatory indicators including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and incidence of adverse reactions were compared between the two groups. Results After treatment, the levels of FPG, 2hBG, HbA1C, Scr, BUN, TNF-α and IL-6 in the combination group were lower than those in the single group (P<0.05), while the GFR in the combination group was higher than that in the single group (P<0.05). There was no significant difference in the incidence of adverse reactions between the combination group (11.11%, 3/27) and the single group (3.85%, 1/26),P>0.05. Conclusions Finerenone combined with telmisartan has a significant effect in the treatment of DN, which can reduce renal inflammation, alleviate insulin resistance, reduce blood glucose level, and improve renal function in patients, with fewer adverse reactions.
Abstract
Objective To investigate the clinical effect of finerenone combined with telmisartan in the treatment of diabetic nephropathy (DN). Methods Fifty-three patients with DN admitted to Luohe Second People’s Hospital from May 2021 to April 2023 were retrospectively selected. And they were divided into a single group (26 cases, treated with telmisartan) and a combination group (27 cases, treated with finerenone combined with telmisartan) according to the treatment method. The levels of blood glucose indexes including fasting blood glucose (FPG), 2-hour postprandial blood glucose (2hBG) and glycosylated hemoglobin (HbA1C), renal function assessed by serum creatinine (Scr), blood urea nitrogen (BUN) and glomerular filtration rate (GFR), inflammatory indicators including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and incidence of adverse reactions were compared between the two groups. Results After treatment, the levels of FPG, 2hBG, HbA1C, Scr, BUN, TNF-α and IL-6 in the combination group were lower than those in the single group (P<0.05), while the GFR in the combination group was higher than that in the single group (P<0.05). There was no significant difference in the incidence of adverse reactions between the combination group (11.11%, 3/27) and the single group (3.85%, 1/26),P>0.05. Conclusions Finerenone combined with telmisartan has a significant effect in the treatment of DN, which can reduce renal inflammation, alleviate insulin resistance, reduce blood glucose level, and improve renal function in patients, with fewer adverse reactions.
关键词
糖尿病肾病/非奈利酮/替米沙坦/肾功能
Key words
Diabetic nephropathies/Finerenone/Telmisartan/Renal function
万方数据